The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback